Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223314 | 0.92 | CHRM3 (0.45) | CHRM3RAF1BRAF | |
| SCHEMBL6414749 | 0.89 | CHRM3 (0.46) | CHRM3RAF1BRAF | |
| SCHEMBL6227746 | 0.89 | CHRM3 (0.47) | CHRM3RAF1BRAF | |
| SCHEMBL6415573 | 0.89 | CHRM3 (0.49) | CHRM3CHRM2CHRM1RAF1BRAF | |
| SCHEMBL6226880 | 0.89 | CHRM3 (0.50) | CHRM3RAF1BRAF | |
| SCHEMBL6416937 | 0.89 | CHRM3 (0.49) | CHRM3RAF1BRAF | |
| SCHEMBL6414791 | 0.89 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6227008 | 0.88 | CHRM3 (0.47) | CHRM3RAF1BRAF | |
| SCHEMBL6415636 | 0.88 | CHRM3 (0.46) | CHRM3RAF1BRAF | |
| SCHEMBL6419489 | 0.88 | RAF1 (0.45) | CHRM3RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885USP30 1800/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.